As the GLP-1 lawsuits demonstrate, using brand names, mimicking trade dress, or making any claims of superiority or FDA approval is a direct invitation for a lawsuit
Its approval was based on a phase 3 study demonstrating a 2-3-fold improvement in MASH resolution and 10% absolute improvement in rates of fibrosis improvement by at least one stage
Hair loss occurs in 4-6% of patients using GLP-1 medications such as Mounjaro, Wegovy, and Zepbound for weight loss
They also come with a high price-tag
Notably, glycemic variability cannot be captured by sparse SMBG measurements, but it can be detected by CGM almost continuous-time profiles
Last but not the least, one of the mouse-based studies gave evidence of Melanotan II reversing some of the autistic features (10), but this aspect of study needs more research